Working… Menu

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00117312
Recruitment Status : Terminated (After 190 weeks [7 patients left] it was terminated for administrative reasons)
First Posted : July 6, 2005
Results First Posted : March 20, 2009
Last Update Posted : May 23, 2011
Information provided by:
Ferring Pharmaceuticals

Brief Summary:

Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was discontinued.

Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Degarelix Phase 2

Detailed Description:
The data include participants from both the main study (FE200486 CS06; NCT00117949) and the extension study FE200486 CS06A.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Study Start Date : October 2002
Actual Primary Completion Date : November 2005
Actual Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Degarelix

Arm Intervention/treatment
Experimental: Degarelix 40 mg
Degarelix 40 mg (10 mg/mL)
Drug: Degarelix
One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
Other Name: FE200486

Experimental: Degarelix 80 mg
Degarelix 80 mg (20 mg/mL)
Drug: Degarelix
One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
Other Name: FE200486

Experimental: Degarelix 120 mg
Degarelix 120 mg (30 mg/mL)
Drug: Degarelix
One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
Other Name: FE200486

Experimental: Degarelix 160 mg
Degarelix 160 mg (40 mg/mL)
Drug: Degarelix
One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
Other Name: FE200486

Primary Outcome Measures :
  1. Liver Function Tests [ Time Frame: 3 years ]
    The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases >3x ULN and ALT increases >3x ULN with concurrently increased bilirubin >1.5 ULN.

  2. Participants With Markedly Abnormal Change in Vital Signs and Body Weight [ Time Frame: 3 years ]
    Vital signs and body weight included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of participants in each group with normal baseline and markedly abnormal value post-baseline.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Each patient must meet the following inclusion criteria before entry into the study:

  • Has given written consent before any study related activity is performed. A study related activity is defined as any procedure that would not have been performed during the normal management of the patient.
  • Has had sufficient testosterone suppression (as defined in the withdrawal criteria of FE200486 CS06) for at least 28 days.

Exclusion Criteria:

Any patient meeting any of the following exclusion criteria will not be entered into the study:

  • Has been withdrawn from Study FE200486 CS06 due to an adverse event, failure to achieve at least 28 days of testosterone suppression, insufficient prostate-specific antigen (PSA) suppression as defined in Study FE200486 CS06 in the absence of concomitant rise in testosterone level or non-compliance with protocol required procedures.
  • Requires hormonal therapy for neoadjuvant purposes.
  • Requires treatment with any other drug modifying the testosterone level or function.
  • Is considered to be a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy, within 6 months after Visit 1.
  • Has a history of severe asthma requiring daily treatment with inhalation steroids, angioedema or anaphylactic reactions.
  • Has hypersensitivity towards any component of the investigational product.
  • Has had a cancer disease within the last 10 years except for prostate cancer, and surgically removed basocellular or squamous cell carcinoma of the skin.
  • Has a clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, dermatological or infectious disorder or any other condition, including excessive alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the study, as judged by the investigator.
  • Any clinically significant laboratory abnormalities which, in the judgment of the investigator, would interfere with the patient's participation in this study or evaluation of study results (liver transaminases and bilirubin must be within normal limits).
  • Has a mental incapacity or language barrier precluding adequate understanding or co-operation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00117312

Layout table for location information
United States, California
Advanced Urology Medical Center
Anaheim, California, United States, 92801
South Orange County Medical Research Center
Laguna Woods,, California, United States, 92653
San Bernardino Urological Associates Medical Group
San Bernardino, California, United States, 92404
Western Clinical Research
Torrance, California, United States, 90505
United States, Colorado
Urology Associate PC`
Denver, Colorado, United States, 80210
United States, Florida
SW Florida Urological Associates
Fort Myers, Florida, United States, 33907
Pinellas Urology, Inc.
St. Petersburg, Florida, United States, 33710
United States, Maryland
Drs. Werner, Murdock & Francis, PA
Greenbelt, Maryland, United States, 20770
United States, Nevada
Nevada Urology Associates
Reno, Nevada, United States, 89511
United States, Oklahoma
Urology Specialists of Oklahoma, Inc.
Tulsa, Oklahoma, United States, 74104
United States, Texas
Urology Clinics of NorthTexas, PA
Dallas, Texas, United States, 75231
Urology San Antonio Research
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Ferring Pharmaceuticals
Layout table for investigator information
Study Director: Clinical Development Support Ferring Pharmaceuticals

Layout table for additonal information
Responsible Party: Clinical Development Support, Ferring Pharmaceuticals Identifier: NCT00117312     History of Changes
Other Study ID Numbers: FE200486 CS06A
First Posted: July 6, 2005    Key Record Dates
Results First Posted: March 20, 2009
Last Update Posted: May 23, 2011
Last Verified: May 2011
Keywords provided by Ferring Pharmaceuticals:
Prostate Cancer
Androgen ablation therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases